INFLUENCE OF MILDRONATE ON EFFICIENCY OF ANTIANGINAL THERAPY IN PATIENTS WITH STABLE BURDEN ANGINA

Aim. To study influence of mildronate (M) on treatment efficiency of patients with ischemic heart disease (IHD), receiving standard antianginal therapy (AAT)

Materials and methods. Double-blind, randomized, placebo-controlled study was carried out in parallel groups. All patients continued the ear￾lier prescribed AAT without changes. After control period (10-14 days) was over, randomization of patients either to the treatment group (M 500mg twice per day), or to the control group (placebo (Pl) twice per day) was made for 6 weeks therapy. Criterion of treatment efficiency: increase in dura￾tion of trial with burden on treadmill (TB), decrease in angina attack frequency (AA) and reduction in nitroglycerin taking (NTT). TB was carried out at the beginning (TB-1), at the end of the control period (TB-2), and at the end of the treatment (TB-3).

Results. TB-1 and TB-2 had good reproducibility, their duration didn’t differ. At the end of the treatment additionally with M, growth in duration of TB-3 (p=0,002) was registered, while there was no growth of TB duration with the Pl treatment (p=0,07). During the treatment decrease in AA number both with M (p=0,002), and with Pl (p=0,02) was noted. With M treatment decrease in NTT treatment (p=0.02) was observed, while NTT with Pl didn’t change (p=0,7). Number of side effects, registered with M and Pl, didn’t differ.

Conclusion. Mildronate provides additional benefits for patients with IHD with stable burden angina, when they do not reach desired effect with the prescribed AAT.

1. World Health Organization, “The World Health Report 2002. Reducing risk, promoting healthy life ”, http://www.who.int.

2. Thadani U, “Current medical management of chronic stable angina”, J Cardiovasc Pharma-col Therapeut. (2004); 9 (suppl.1): S11-S29.

3. Gibbon RJ,Abrams J, Catterjee K et al., “ACC/AHA 2002 guideline update for the manage-ment of patients with chronic stable angina – Summary article: A report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Chronic Stable Angina)”, Circulation 2003;107: 49-158.

4. Pepine CJ, Wolff AA. A controlled trial with a novel anti-ischemic agent, ranolasine, in chronic stable angina pectoris that is responsive to conventional antianginal agents. Am J Cardiol 1999; 84:46-50.

5. Lopaschuk GD, Wall SR, Olley PM, Davies NJ. Etomoxir a carnitine palmitoyl transferase I inhibitor, protects hearts from fatty acidinduced ischemia injury independent of changes in long chain acylcarnitine. Circ Res. 1988; 63:1036-1043.

6. Карпов Р.С., Кошельская О.А., Дудко В.А., Ханская Н.В. Возможности метаболической терапии милдронатом у больных стеокрадией. I Российский нац. конгресс «Человек и лекарство» Тез.докл. – М.,1992. с.162.

7. Дудко В.А., Кошельская О.А., Соколов А.А. Применение милдроната у больны стенокардией. Врач.дело. 1989; ?10: с.64-67.

8. SAS/STAT User’s Guide, Version 6, Forth Edition, Vol.1&2, SAS Institute Inc., Cary, NC, USA,-1990.

9. Detry JM, Seller P, Pennaforte S, Cokkinos D, Dargie H, Mathes P, on behalf of the Trimetazidine European Multicenter Study Group. Trimetazidine: a new concept in the treatment of angina. Comparison with propranolol in patients with stable angina. Br J Clin Pharmacol. 1994; 37: 279-288.

10. Dalla-Volta S, Maraglino G, Della-Valentina P, et al. Comparison of trimetazidine with nifedipine in effort angina: double-blind, crossover study. Cardiovasc Drugs Ther. 1990; 4: 853-860.

11. Сыркин А.Л., Лепахин В.К., Фитилев С.Б., Иванова Э.В., Титарова Ю.Ю., Левин А.М. Триметазидин при стабильной стенокардии напряжения у больных старше 65 лет (TRIMEP – Timetazidine in elderly people), Кардиология, 2002;6:24-31.

12. Szwed H, Sadowski Z, Elikovski W et al. Combination treatment in stable effort angina using trimetazidine and metaprolol. Results of a randomized, double-blind, multicentre study (TRIMPOL II). Eur Heart J. 2001; 22:2267-2274.